Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Total Current Liabilities (2021 - 2025)

Lyra Therapeutics has reported Total Current Liabilities over the past 5 years, most recently at $9.5 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $9.5 million for Q4 2025, down 24.61% from a year ago — trailing twelve months through Dec 2025 was $9.5 million (down 24.61% YoY), and the annual figure for FY2025 was $9.5 million, down 24.61%.
  • Total Current Liabilities for Q4 2025 was $9.5 million at Lyra Therapeutics, roughly flat from $9.5 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for LYRA hit a ceiling of $22.0 million in Q1 2022 and a floor of $4.2 million in Q1 2021.
  • Median Total Current Liabilities over the past 5 years was $14.1 million (2023), compared with a mean of $14.1 million.
  • Biggest five-year swings in Total Current Liabilities: surged 426.74% in 2022 and later plummeted 42.09% in 2025.
  • Lyra Therapeutics' Total Current Liabilities stood at $18.2 million in 2021, then dropped by 20.69% to $14.5 million in 2022, then surged by 35.43% to $19.6 million in 2023, then plummeted by 35.55% to $12.6 million in 2024, then decreased by 24.61% to $9.5 million in 2025.
  • The last three reported values for Total Current Liabilities were $9.5 million (Q4 2025), $9.5 million (Q3 2025), and $11.2 million (Q2 2025) per Business Quant data.